Warburg Pincus has acquired Pharma Intelligence, a provider of specialist intelligence, data, and software for clinical trials, drug development and regulatory compliance, from Informa PLC. No financial terms were disclosed. Mubadala Investment Company joined Warburg Pincus in the investment.
LONDON, February 10, 2022 — Warburg Pincus, a leading global growth investor, today announced the acquisition of Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa PLC (LSE:INF.L), the international B2B markets knowledge services and business intelligence group. Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment. The investors plan to extend the company’s leading position in the pharmaceutical data and analytics market, investing in the creation of innovative products for its customers. Informa will retain 15% ownership in the company.
Pharma Intelligence is a leading operator in the $22 billion global pharma and life sciences analytics markets. The company holds the leading position in the clinical trial intelligence space, providing insights on patient enrollment and demographics, trial progress, individual trial sites and investigators for more than 375,000 clinical trials across 180 countries. The company’s solutions are used by 3,000 pharmaceutical companies and CROs in their clinical trial design, commercial strategy, and regulatory compliance processes to maximize the likelihood of success of introducing products to market.
The acquisition includes Informa’s full portfolio of specialist brands which includes the Citeline suite of products, Trialtrove, Sitetrove, Pharmaprojects and Citeline branded products, as well as Biomedtracker, Clinerion, Datamonitor Healthcare, Pink Sheet, Scrip, Skipta, and TrialScope.
Stephen A. Carter, Group Chief Executive, Informa PLC, said “We received significant interest in the Pharma Intelligence business. We are delighted to partner with Warburg Pincus and share their view on its future growth potential, hence, we welcomed an agreement that represented value today and growth and value tomorrow.’’
Adarsh Sarma, co-head of Europe and Chandler Reedy, Head of Strategic Investments at Warburg Pincus said ‘’Pharma Intelligence is an increasingly important company with tremendous growth potential. We believe that demand for its services will increase as the world becomes more data driven and focused on using predictive analytics to solve health issues and major diseases. As one of the world’s largest investors in pharma, health tech and b2b information services, Warburg Pincus is uniquely placed to help the company achieve its growth potential. We look forward to continuing to work closely with Informa as we invest in and grow the company, building on the great work undertaken already.’’
Jay Nadler, Senior Adviser to Warburg Pincus said ‘’Pharma Intelligence’s services are of vital importance to the pharma, biotech, and healthcare community. It’s a fast-growing company with outstanding products and people, and a commitment to best-in-class service with deep expertise in sectors that Warburg Pincus understands extremely well. We look forward to partnering with the company’s employees and customers, working together to drive innovation to introduce more efficiency into the drug development lifecycle.’’
David Reis and Amr Kronfol, Managing Directors at Warburg Pincus said ” As a leading growth investor, the potential for innovation and growth are central to our investment approach and this applies to our strategy for Pharma Intelligence. We will increase focus and investment for innovation and product development to address important customer needs, working in partnership with Informa, Jay Nadler, and the Pharma Intelligence team.’’
Warburg Pincus has a strong record of investing in innovative healthcare technology companies, including Aetion, Insilico, GHX, Experity, Nuance Communications, and Modernizing Medicine. Notable investments in information services include, Accelya, Interactive Data Corporation, Fortius, Gordian and MLM Information Services. Warburg Pincus has also undertaken several successful recent carve-outs, including Constructionline / Fortius from Capita and 1&1 Internet from United Internet.
The acquisition is expected to complete within the first half of 2022, subject to any relevant regulatory clearances.
Informa is a leading international B2B markets, knowledge services and business intelligence Group. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and opportunities to connect and learn. For more information, please visit www.informa.com
About Pharma Intelligence
A leading operator in the $22bn global pharma and life sciences analytics markets, Pharma Intelligence delivers highly valued specialist intelligence and data in areas of Clinical Trials, Drug Development and Regulatory Compliance. Its portfolio of specialist brands includes the Citeline suite of products (Citeline Predict, Citeline Engage, Citeline Connect), Biomedtracker, Datamonitor Healthcare, Scrip, Pink Sheet and TrialScope.